CYTEK BIOSCIENCES, INC. Cytek Biosciences, Inc. Share Price
Equities
CTKB
US23285D1090
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.76 USD | +2.31% |
|
-2.70% | -36.84% |
| 03-20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
| 03-19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
| Sales 2024 * | 208M 16.65B | Sales 2025 * | 247M 19.79B | Capitalization | 756M 60.53B |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -720M | Net income 2025 * | 7M 560M | EV / Sales 2024 * | 2.57 x |
| Net cash position 2024 * | 221M 17.67B | Net cash position 2025 * | 235M 18.8B | EV / Sales 2025 * | 2.11 x |
| P/E ratio 2024 * |
-160
x | P/E ratio 2025 * |
65.5
x | Employees | 676 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cytek Biosciences, Inc.
More recommendations
More press releases
| 1 day | +2.31% | ||
| 1 week | -2.70% | ||
| Current month | -14.16% | ||
| 1 month | -8.43% | ||
| 3 months | -32.08% | ||
| 6 months | +25.22% | ||
| Current year | -36.84% |
1 week
5.49
6.03
1 month
5.497.02
Current year
5.499.33
1 year
3.8012.31
3 years
3.8028.70
5 years
3.8028.70
10 years
3.8028.70
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Yan
FOU | Founder | 61 | 30/11/14 |
Wen Bin Jiang
FOU | Founder | 60 | 30/11/14 |
Chris Williams
COO | Chief Operating Officer | 55 | 30/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donnie Hardison
BRD | Director/Board Member | 74 | 31/05/22 |
Deborah Neff
BRD | Director/Board Member | 71 | - |
Jack Ball
BRD | Director/Board Member | 77 | 12/11/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 27 M€ | -5.03% | - | |
| 0.11% | 0 M€ | 0.00% | - | |
| 0.11% | 45 M€ | +0.20% | ||
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 5.76 | +2.31% | 277,809 |
| 25/04/24 | 5.63 | -0.53% | 541,272 |
| 24/04/24 | 5.66 | -2.58% | 477,762 |
| 23/04/24 | 5.81 | +0.17% | 376,789 |
| 22/04/24 | 5.8 | -2.03% | 523,233 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.76
USD
Average target price
10
USD
Spread / Average Target
+73.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.84% | 756M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- CTKB Stock
